Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14838637 | 1.00 | MAPK1 (0.51) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL14830273 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL1136065 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL16416468 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL1136066 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL15221118 | 0.86 | MAPK1 (0.52) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL498073 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL469776 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL12348258 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF2F10 | |
| SCHEMBL28025617 | 0.85 | MAPK1 (0.51) | MAPK1HPGDTSHRF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150299160-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| EP-2838897-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Ranbaxy Laboratories Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| WO-2013156936-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| CN-101610767-B | Combination therapy of substituted oxazolidinones | BAYER SCHERING PHARMA AG | 2013-03-13 | — | — | CN | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | MAPK1 2346/4885HPGD 51/4885TSHR 2864/4885 |
| US-20150299160-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | VKORC1, CYP3A4, TFPI | MAPK1 2718/4885HPGD 144/4885TSHR 2502/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | MAPK1 3056/4885HPGD 218/4885TSHR 4106/4885 |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | MAPK1 1832/4885HPGD 342/4885TSHR 4123/4885 |
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | MAPK1 3699/4885HPGD 25/4885TSHR 3344/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | MAPK1 3637/4885HPGD 241/4885TSHR 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.